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Objective: To perform an extensive screening for mu-
tations of amyotrophic lateral sclerosis (ALS)–related
genes in a consecutive cohort of Sardinian patients, a ge-
netic isolate phylogenically distinct from other Euro-
pean populations.
Design: Population-based, prospective cohort study.
Patients:A total of 135 Sardinian patients with ALS and
156 healthy control subjects of Sardinian originwhowere
age- and sex-matched to patients.
Intervention: Patients underwent mutational analysis
for SOD1, FUS, and TARDBP.
Results:Mutational screening of the entire cohort found
that 39 patients (28.7%) carried the c.1144G!A
(p.A382T) missense mutation of the TARDBP gene. Of
these, 15 had familial ALS (belonging to 10 distinct pedi-
grees) and 24 had apparently sporadic ALS. None of the
156 age-, sex-, and ethnicity-matched controls carried the
pathogenic variant. Genotype data obtained for 5 ALS
cases carrying the p.A382T mutation found that they
shared a 94–single-nucleotide polymorphism risk hap-
lotype that spanned 663 Kb across the TARDBP locus on
chromosome 1p36.22. Three patientswithALSwho carry
the p.A382Tmutation developed extrapyramidal symp-
toms several years after their initial presentationwithmo-
tor weakness.
Conclusions: The TARDBP p.A382T missense muta-
tion accounts for approximately one-third of all ALS cases
in this island population. These patients share a large risk
haplotype across the TARDBP locus, indicating that they
have a common ancestor.
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T HE IDENTIFICATION OF THEtransactivation responseDNA-binding protein(TDP-43) as themajor con-stituent of ubiquitin inclu-
sions in amyotrophic lateral sclerosis (ALS)
and frontotemporal dementia (FTD) was
a major advance in our understanding of
the pathogenesis of these neurodegenera-
tive diseases.1 Subsequently, it was dis-
covered that mutations in the TARDBP
gene located on chromosome 1p36 (which
encodes the TDP-43 protein) explain ap-
proximately 4% of familial ALS cases2 and
a smaller proportion of FTD cases.3
Previous studies have shown that ge-
netic studies of population isolates repre-
sent a powerful method of finding genes
that are causative of ALS.4 Sardinia, with
a population of 1.7 million, is the second
largest Mediterranean island, located 120
miles west of the main Italian coastline.
Despite numerous invasions over themil-
lennia, genetic, linguistic, and archaeo-
logical studies indicate that Sardinians have
a phylogeny distinct from other Europe-
ans, including mainland Italians.4-7 In-
deed, Y-chromosome analysis suggests a
largely pre-Neolithic settlement of Sardinia
with little subsequent gene flow from out-
side populations despite Phoenician-
Carthaginian (535-238 before Christ) and
Roman (238 before Christ to 476 anno
Domini) dominations of the island.8 The
island population has a uniquely high in-
cidence of several autoimmune diseases
such as type 1 diabetes9 andmultiple scle-
rosis10 and of monogenic diseases such as
Wilson disease.11
There are no population-based pro-
spective studies on the incidence of ALS
in Sardinia. A recent epidemiological study
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found the frequency of the condition on the island to be
1.88 per 100 000 inhabitants,12 which is less than that re-
ported elsewhere in Europe.13,14 However, the catch-
ment area of that study was limited to a single province
of Northern Sardinia (representing 19% of the island
population), and there are reports from the lay press sug-
gesting that the incidence of this fatal neurodegenera-
tive disease is higher than expected in certain parts of
Sardinia.
In this article, we report the results of our mutational
screening of the SOD1, TARDBP, and FUS genes in a co-
hort of 135 Sardinian patients with ALS.
METHODS
SUBJECTS
DNA samples were obtained from a consecutive series of pa-
tients diagnosed with definite, probable, probable laboratory-
supported, or possible ALS15 who attended the neurology de-
partments at theUniversity ofCagliari, the capital city of Sardinia
situated in the south of the island; the University of Sassari in
the north of the island; and the Hospital of Nuoro located in
the center of the island. All patients were of Sardinian origin
by self-report and were enrolled during a 12-month period be-
tween April 2009 and March 2010. Patients underwent neu-
ropsychological testing for the diagnosis of frontotemporal cog-
nitive and behavioral syndromes in ALS according to the
consensus criteria.16 The diagnosis of Parkinson disease was
based on the United Kingdom Parkinson disease society brain
bank diagnostic criteria.17 Controls consisted of 156 healthy in-
dividuals of Sardinian origin, matched to patients by age and
sex. Demographics and clinical features of the cases and con-
trols are shown in eTable 1 (http://www.archneurology.com).
The ethical committees of all involved institutions approved
the study, and all patients and controls gave written informed
consent.
MUTATIONAL SCREENING
All patients underwentmutational analysis for SOD1, FUS, and
TARDBP. Specifically, all of the coding exons and 50 base pairs
of the flanking intron-exon boundaries of SOD1, FUS, and
TARDBPwere amplifiedusingpolymerase chain reaction (primer
sequences available on request), sequenced using the BigDye
Terminator v3.1 sequencing kit (Applied Biosystems Inc, Fos-
ter City, California), and run on an ABI PRISM 3100-Avant ge-
netic analyzer (Applied Biosystems).
GENOTYPING
Genotyping was performed on a representative sample of fa-
milial and sporadic ALS cases carrying the p.A382T mutation
using Infinium Human660W SNP chip arrays (Illumina, Inc,
San Diego, California), which assay 561 490 single-nucleotide
polymorphisms across the genome. These data were used to
determine the degree of relatedness of samples (quantified as
the pi-hat metric) by applying the identity-by-descent algo-
rithm (–genome) within the PLINK toolset.18
RESULTS
A total of 135 patients with ALS were consecutively en-
rolled at the 3 main ALS clinics serving the Sardinian
population. These cases were collected during a 1-year
time period, and our cohort likely represents almost com-
plete case ascertainment of prevalent cases in the Sardin-
ian population for that time period. Almost a quarter of
the cases (n=31; 23.0%) reported a familial history of ALS
with autosomal dominant inheritance.
Mutational screening of the entire cohort found that
39 patients (28.7%) carried the known c.1144G!A
(p.A382T) missense mutation of the TARDBP gene. Of
these, 15 had familial ALS (belonging to 10 distinct pedi-
grees) and 24 had apparently sporadic ALS. Patients who
carried the TARDBP p.A382T missense mutation origi-
nated from all parts of the island. One apparently spo-
radic case was homozygous for the p.A382T missense
mutation. None of the 156 age-, sex-, and ethnicity-
matched healthy controls carried the p.A382Tmutation.
Of the remaining 96patients (71.3%)whodid not carry
the p.A382T mutation, 2 brothers carried a novel
c.287C!G (p.A95G) missense mutation of the SOD1
gene. Based on these 2 cases, the frequency of SOD1mu-
tations wasapproximately8% of individuals with famil-
ial ALS and 1.4% of the whole Sardinian population with
ALS. No other mutations of the SOD1, TARDBP, or FUS
genes were identified.
Genotype data obtained for 5 ALS cases carrying the
p.A382Tmutation (3 familial cases from 2 ostensibly un-
related families and 2 sporadic cases) found that they
shared a 94–single-nucleotide polymorphism risk hap-
lotype spanning 663 Kb across the TARDBP locus on
chromosome 1p36.22 (see eTable 2 for risk haplotype).
Identity-by-descent analysis based on the same genome-
wide genotyping data confirmed that the sporadic cases
and the familial caseswere cryptically related to each other
(mean [SD] pi-hat,0.21 [0.005], indicating that the ap-
parently sporadic cases carrying the p.A382T variantwere
roughly second- to third-degree relatives of familial cases
carrying the same mutation).
The demographics and clinical characteristics of the pa-
tients with and without the p.A382T TARDBP mutation
are shown in Table1. Frontal lobe dysfunction, flail arm
Table 1. Demographic and Clinical Characteristics of the
Patients Carrying the TARDBP p.A382T Missense Mutation
and of the Nonmutated Cases
Characteristic
Patients, No./Total (%)
P Value
With p.A382T
(n=39)
No p.A382T
(n=96)
Sex .29
Male 28 60
Female 11 36
Age at onset,
mean (SD), y
57.9 (12.2) 59.9 (10.1) .34
Type of onset 6/33 21/75 .38
Bulbar 6 21
Spinal 33 75
FALS 15 (38.5) 17 (17.7)a .01
FTD 12 (30.8) 9 (9.4) ".001
Abbreviations: FALS, familial amyotrophic lateral sclerosis;
FTD, frontotemporal dementia.
aTwo patients carry the p.A95G SOD1 missense mutation.
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variant ofALS, anduppermotor neuron–predominantALS
weremore commonamong Sardinian patients carrying the
TARDBP p.A382T mutation than among noncarriers
(Table 2). Three patients with ALS who carried the
p.A382T mutation developed extrapyramidal symptoms
several years after their initial presentation with motor
weakness. The first patientwas a 57-year-oldmanwhopre-
sented with proximal leg weakness and subsequently de-
veloped a rigid hypokinetic parkinsonian syndrome and
frontotemporal dementia. He died 6 years after symptom
onset.His older brother,who also carried the p.A382Tmu-
tation, developed uppermotor neuron–predominant ALS
at 70 years of age and was alive 6 years after the onset of
ALS without evidence of parkinsonism or FTD. The sec-
ond patient was a 37-year-old man who initially pre-
sented with leg weakness but then progressed to mani-
fest parkinsonism and external ophthalmoplegia 5 years
later. He remains alive 12 years after symptom onset. Fi-
nally, we identified a 48-year-old man who also pre-
sented with upper motor neuron–predominant ALS that
was followed 3 years later by the onset of rigid hyperki-
netic parkinsonism. Neuropsychological testing con-
firmed frontal lobe dysfunction consistent with FTD. Of
note, the patient had a history of a vocal and motor tics
disorder since childhood that had been treatedwith halo-
peridol for less than 2 years when aged 18 years. This pa-
tient carries a homozygous A382Tmissensemutation and
was alive 4 years after the onset of ALS.
COMMENT
Ourmutational screening study of Sardinian patientswith
ALS found that a single missense mutation in TARDBP
accounts for approximately one-third of all ALS cases in
this island population. Furthermore, these ALS patients
shared a large risk haplotype across the TARDBP locus,
indicating that they had a common ancestor and were
part of a larger kindred. This founder effect is compa-
rable with that recently described for the chromosome
9p21ALS-FTD locus in the Finnish population4 and high-
lights the power of performing genetic studies in popu-
lation isolates with a higher incidence of a disease. In this
regard, it is noteworthy that nearly a quarter of the Sardin-
ian ALS cases in our consecutive series of prevalent pa-
tients had a known family history of ALS, which is con-
siderably higher than theapproximately5% reported by
population-based epidemiological studies in other Eu-
ropean populations.13,14
The TARDBP p.A382T missense mutation has been
previously described in 2 French patients with ALS and
11 patients living on mainland Italy.19-21 Microsatellite
analysis suggested that at least a portion of these French
and Italian patients carried the same 2.4-Mb haplotype
on chromosome 1.21 The high marker density of the Il-
lumina HumanHap660W genotyping array used in our
study allowed this haplotype to be narrowed to a 663-Kb
region containing the TARDBP gene locus. DNAwas not
available to test if themainland Italian or French samples
carried the same haplotype, but the geographical close-
ness of these cases makes it likely that all of them arose
from a single mutational event.
Nearly two-thirds of the patients (n=24) carrying the
p.A382Tmutationwere classified as having sporadic ALS.
Although it is possible that some of these cases arose from
multiple mutational events affecting the same nucleotide,
ourdatastronglysupport thenotionthat thesecasesarepart
of thesameextendedpedigree:genome-wideanalysisdem-
onstratedthatboththefamilialandsporadicsamplesshared
anaverageof21%of their genomewitheachother, indicat-
ing that they had a common ancestor as recently as 3 gen-
erationsago.Cryptic relatedness, inwhich2 individualsare
related to each other without their knowledge, is a well-
described issue in ALS andmay arise from poor diagnosis
inpastgenerations, incompleteknowledgeof familyhistory,
andevenvaryingmanifestationsofmotorandcognitivedys-
functionamongmutationcarrierswithin thesamefamily.22
The relative late age of symptomonset in patients carrying
thep.A382Tmutationalsoindicatesthatthispathogenicvari-
ant is only fully penetrant by the eighth decade of life and
thatmutationcarriers inpreviousgenerationsmayhavedied
of other diseases prior to developingmotor neurondegen-
eration. An alternative possibility is that the p.A382Tmu-
tationrepresentsarisk factor forALSinthesesporadiccases
rather thanbeing thedirect cause of disease. Although this
possibility cannotbe fully excluded, the lackof thisknown
pathogenicmutationinneurologicallynormalSardiniancon-
trolsamples(or inotherpopulations), thesharedhaplotype,
andrelatednessamongthecasescarryingthemutationwould
not support this hypothesis.
Sardinian patients carrying the p.A382Tmutation had
a heterogeneous spectrum of ALS phenotypes, a pattern
that has been observed formutations in other ALS genes.23
Despite these observations, the flail arm variant of ALS
occurred with greater than expected frequency among
mutation carriers. This clinical variant has also been pre-
viously described in patients with TARDBPmutations,24
and all 7 French patients with the p.A382T mutation
manifested a lower motor neuron predominant form of
the disease with onset in the upper limbs.20
We observed extrapyramidal symptoms in multiple
Sardinian patients with ALS carrying the TARDBP
p.A382T mutation, representing the first time that par-
kinsonism has been described in individuals with mu-
tations in this gene.25 Some caution is required in inter-
preting these findings. First, one of the patients with
extrapyramidal symptoms alsomanifested external oph-
thalmoplegia, a findingmore commonly associated with
mitochondrial disorders. Though supranuclear palsy has
Table 2. Clinical Phenotypes of Patients Carrying
the TARDBP p.A382T Missense Mutation
and of Nonmutated Cases
Phenotype
Patients, No. (%)
P Value
With p.A382T
(n=39)
No p.A382T
(n=96)
Classic 15 (38.5) 59 (61.4) .01
Pyramidal 8 (20.5) 8 (8.3) .05
Flail leg 2 (5.1) 6 (6.3) .98
Flail arm 8 (20.5) 2 (2.1) ".001
Bulbar 6 (15.3) 21 (21.9) .38
(REPRINTED) ARCH NEUROL PUBLISHED ONLINE JANUARY 10, 2011 WWW.ARCHNEUROL.COM
E3
©2011 American Medical Association. All rights reserved.
 at National Institutes of Health, on January 10, 2011 www.archneurol.comDownloaded from 
already been described in a patient with a different
TARDBP mutation,26 the mitochondrial genome of our
case was not sequenced, so the existence of a secondmi-
tochondrial disease-causing variant in addition to his
known pathogenic p.A382Tmutation remains possible.
Second, it is possible that the neuroleptic medications
taken by the third patient for treatment of childhood-
onset tic disorder contributed to his extrapyramidal symp-
toms, though it is noteworthy that thesemedicationswere
discontinuedmore than 30 years prior to the onset of par-
kinsonism. Third, parkinsonism is a well-recognized fea-
ture of ALS,27,28 suggesting that the finding of 3 cases in
a cohort of this size may have been a chance occur-
rence. In addition, the diagnosis of extrapyramidal signs
in patients with ALS is often complicated by the pres-
ence of upper and lower motor neuron signs inherent to
the disease. Finally, autopsy material was not available
from any of the patients with extrapyramidal symp-
toms, so histopathological confirmation of substantia ni-
gra involvement was not possible.
Despite this, we believe that our observations, taken
together with the previous report of chorea in a patient
with a TARDBP mutation,26 expand the clinical spec-
trum associated with mutations in this gene to include
basal ganglia dysfunction. Given that pathological depo-
sition of TDP-43 in the central nervous system has been
described in a variety of neurological disorders,29 it is per-
haps not surprising that TARDBP mutations can be as-
sociated with a wide range of neurodegeneration pro-
cesses with corresponding clinical manifestations. The
basis of this pathological and phenotypic heterogeneity
is not clear, though genetic or environmental factorsmay
influence the precise clinical manifestations of TARDBP
mutation carriers. These genotype-phenotype observa-
tions suggest that screening of Sardinian patients with
diverse neurological diseases for the TARDBP p.A382T
mutationmay reveal additional unrecognized clinical con-
sequences of this pathogenic variant.
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